Abstract
Nitric oxide (NO), a molecular messenger synthesized by nitric oxide synthase (NOS) from L-arginine and molecular oxygen, is involved in a number of physiological and pathological processes in mammalians. Three structurally distinct isoforms of NOS have been identified: neuronal (nNOS), endothelial (eNOS) and inducible (iNOS). Although NO mediates several physiological functions, overproduction of NO by nNOS has been reported in a number of clinical disorders including acute (stroke) and chronic (schizophrenia, Alzheimers, Parkinsons and AIDS dementia) neurodegenerative diseases, convulsions and pain overproduction of NO by iNOS has been implicated in various pathological processes including septic shock, tissue damage following inflammation and rheumatoid arthritis. On the contrary, NO produced by eNOS has only physiological roles such as maintaining physiological vascular tone. Accordingly, selective inhibition of nNOS or iNOS vs eNOS may provide a novel therapeutic approach to various diseases in addition selective inhibitors may represent useful tools for investigating other biological functions of NO. For these reasons, after the identification of N-methyl-L-arginine (L-NMA) as the first inhibitor of NO biosynthesis, design of selective NOS inhibitors has received much attention. In this article the recent developments of new molecules endowed with inhibitory properties against the various isoforms of NOS are reviewed. Major focus is placed on structure-activity-selectivity relationships especially concerning compounds belonging to the non-aminoacid-based inhibitors.
Keywords: Nitric Oxide Synthase, (schizophrenia, non-aminoacid-based inhibitors, L-ARGININE ANALOGUES, L-thiocitrulline, L-homothiocitrulline, 2-Iminopiperidines, Homopiperidines, Phenyl imidazole, Neuronal nitric oxide synthase, High spin heme-complex
Current Pharmaceutical Design
Title: Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors
Volume: 8 Issue: 3
Author(s): L. Saleron, V. Sorrenti, C. Di Giacomo, G. Romeo and M. A. Siracusa
Affiliation:
Keywords: Nitric Oxide Synthase, (schizophrenia, non-aminoacid-based inhibitors, L-ARGININE ANALOGUES, L-thiocitrulline, L-homothiocitrulline, 2-Iminopiperidines, Homopiperidines, Phenyl imidazole, Neuronal nitric oxide synthase, High spin heme-complex
Abstract: Nitric oxide (NO), a molecular messenger synthesized by nitric oxide synthase (NOS) from L-arginine and molecular oxygen, is involved in a number of physiological and pathological processes in mammalians. Three structurally distinct isoforms of NOS have been identified: neuronal (nNOS), endothelial (eNOS) and inducible (iNOS). Although NO mediates several physiological functions, overproduction of NO by nNOS has been reported in a number of clinical disorders including acute (stroke) and chronic (schizophrenia, Alzheimers, Parkinsons and AIDS dementia) neurodegenerative diseases, convulsions and pain overproduction of NO by iNOS has been implicated in various pathological processes including septic shock, tissue damage following inflammation and rheumatoid arthritis. On the contrary, NO produced by eNOS has only physiological roles such as maintaining physiological vascular tone. Accordingly, selective inhibition of nNOS or iNOS vs eNOS may provide a novel therapeutic approach to various diseases in addition selective inhibitors may represent useful tools for investigating other biological functions of NO. For these reasons, after the identification of N-methyl-L-arginine (L-NMA) as the first inhibitor of NO biosynthesis, design of selective NOS inhibitors has received much attention. In this article the recent developments of new molecules endowed with inhibitory properties against the various isoforms of NOS are reviewed. Major focus is placed on structure-activity-selectivity relationships especially concerning compounds belonging to the non-aminoacid-based inhibitors.
Export Options
About this article
Cite this article as:
Saleron L., Sorrenti V., Giacomo Di C., Romeo G. and Siracusa A. M., Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors, Current Pharmaceutical Design 2002; 8 (3) . https://dx.doi.org/10.2174/1381612023396375
DOI https://dx.doi.org/10.2174/1381612023396375 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Current Gene Therapy Clearance of Genetic Variants of Amyloid β Peptide by Neuronal and Non-neuronal Cells
Protein & Peptide Letters Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics
Current Drug Safety The Cholinergic System: An Emerging Drug Target for Schizophrenia
Current Pharmaceutical Design The Association of Folic Acid Deficiency and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Novel Detection System for Plant Protein Production of Pharmaceuticals and Impact on Conformational Diseases
Protein & Peptide Letters Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science Resistin and Oxidative Stress in Non-Diabetic Obstructive Sleep Apnea Patients with Nocturnal Hypertension
Current Respiratory Medicine Reviews The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Preface
Current Psychopharmacology Sleep-Related Disorders, Diabetes and Obesity: Understanding the Facts
Current Respiratory Medicine Reviews The Use and Misuse of Exposure Therapy for Obsessive-Compulsive and Related Disorders
Current Psychiatry Reviews Sub-Chronic Exposure of Non-Observable Adverse Effect Dose of Terbufos Sulfone: Neuroinflammation in Diabetic and Non-Diabetic Rats
CNS & Neurological Disorders - Drug Targets Interference of Glycine Transporter 1: Modulation of Cognitive Functions Via Activation of Glycine-B Site of the NMDA Receptor
Central Nervous System Agents in Medicinal Chemistry Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy